

Indivior Publications 2016

Manuscripts

Early-Stage Discovery and Development

1. Micheli F, Cremonesi S, Semeraro T, Tarsi L, Tomelleri S, Cavanni P, Zonzini L, Feriani A, Braggio S, Heidbreder C. Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists. *Bioorg Med Chem*. 2016;26(4):1329-1332. <http://dx.doi.org/10.1016/j.bmcl.2015.12.081>
2. Micheli F, Bernardelli A, Bianchi F, Braggio S, Castelletti L, Cavallini P, Cavanni P, Cremonesi S, Cin MD, Feriani A, Oliosi B, Semeraro T, Tarsi L, Tomelleri S, Wong A, Visentini F, Zonzini L, Heidbreder C. 1,2,4-Triazolyl Octahydropyrrolo[2,3-b]pyrroles: A New Series of Potent and Selective Dopamine D3 Receptor Antagonists. *Bioorg Med Chem*. 2016;24(8):1619-1636. <http://dx.doi.org/10.1016/j.bmc.2016.02.031>
3. Micheli F, Bacchi A, Bernardelli A, Braggio S, Castelletti L, Cavallini P, Cavanni P, Cremonesi S, Dal Cin M, Feriani A, Kajbaf M, Marchiò L, Oliosi B, Pellacani A, Perdona E, Sava A, Semeraro T, Tarsi L, Tomelleri S, Wong A, Visentini F, Zonzini L, Heidbreder C. 1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists. *J Med Chem*. 2016;59(18):8549-8576. <http://dx.doi.org/10.1021/acs.jmedchem.6b00972>

Treatment of Schizophrenia

1. Nasser AF, Henderson DC, Fava M, Fudala PJ, Twumasi-Ankrah P, Kouassi A, Heidbreder C. Efficacy, safety and tolerability of RBP-7000 once monthly risperidone for the treatment of acute schizophrenia: An 8-week, randomized, double-blind, placebo-controlled, multicenter Phase 3 study. *Clin. Psychopharmacology*. 2016;36(2):130-140. <http://dx.doi.org/10.1097/JCP.0000000000000479>
2. Isitt JJ, Nadipelli VR, Kouassi A, Fava M, Heidbreder C. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. *Schizophr Res*. 2016;174(1-3):126-131. <http://dx.doi.org/10.1016/j.schres.2016.03.020>

Treatment of Opioid Use Disorder

1. Liu Y, Li X, Xu A, Heidbreder C, Nasser AF. Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry. *J Pharm Biomed Anal*. 2016;120:142-152. <http://dx.doi.org/10.1016/j.jpba.2015.12.008>
2. Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, Jones JP III, Heidbreder C. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge with Hydromorphone in Subjects with Opioid Use Disorder. *J Clin Psychopharmacol*. 2016;36(1):18-26. <http://dx.doi.org/10.1097/JCP.0000000000000434>
3. Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF. Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder. *J Clin Pharmacol*. 2016;56(7):806-815. <http://dx.doi.org/10.1002/jcph.665>

4. Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJ. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. *Subst Abuse Rehabil.* 2016;7:131-141. <http://dx.doi.org/10.2147/SAR.S108302>

Abstracts

Treatment of Opioid Use Disorder

1. Laffont CM, Gomeni R, Heidbreder C, Jones JP III, Nasser AF. Population pharmacokinetic modelling after repeated administrations of RBP-6000, a new, subcutaneous formulation of buprenorphine for the treatment of opioid use disorder. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). San Diego, CA; March 8-12, 2016.
2. Wollschlaeger B, Montejano LB, Willson TM, Ronquest NA, Nadipelli VR. Half of commercially insured patients with opioid use disorder receive medication assisted treatment. Proceedings of the 47th Annual Conference of the American Society of Addiction Medicine (ASAM). Baltimore, MD; April 14-17, 2016.
3. Willson TM, Montejano LB, Wollschlaeger BA, Ronquest NA, Nadipelli VR. Real-world dosing patterns among patients receiving buprenorphine for opioid dependence in the United States. Proceedings of the 28th Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting. San Francisco, CA; April 19-22, 2016.
4. Montejano LB, Ronquest NA, Wilson TM, Wollschlaeger BA, Cole AL, Nadipelli VR. How to measure "opioid relapse" in real-world claims data. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington, DC; May 21-25 2016.
5. Zah V, Matveev N, Berjan M, Ruby J. Optimal minimum length of treatment with buprenorphine: an analysis of resource use and costs after medically controlled discontinuation. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington, DC; May 21-25 2016.
6. Zah V, Matveev N, Berjan M, Thompson S, Ruby J. Optimal minimum length of treatment with buprenorphine: an analysis of resource use and costs after medically controlled discontinuation. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC; May 21-25 2016.
7. Brady B, Tkacz J, Nadipelli V, Volpicelli J, Ronquest N, Un H, Ruetsch C. Relapse in opioid use disorder: implications for health care utilization and costs. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC; May 21-25 2016.
8. Tkacz J, Brady B, Nadipelli V, Volpicelli J, Ronquest N, Un H, Ruetsch C. The association between buprenorphine medication-assisted treatment adherence and health care service utilization and costs. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC; May 21-25, 2016.
9. Wollschlaeger BA, Montejano LB, Willson TM, Ronquest NA, Juneau PL, Nadipelli VR. Real-world evidence: buprenorphine adherence predictive of reduced risk of opioid relapse. Proceedings of the 4th Academy of Managed Care Pharmacy (AMCP) Nexus. National Harbor, MD; October 3-6 2016.
10. Wollschlaeger BA, Montejano LB, Willson TM, Ronquest NA, Nadipelli VR. How do patients diagnosed with opioid use disorders compare to the overall US population of individuals with

drug use disorders? Proceedings of the 29th Annual US Psychiatric & Mental Health Congress. San Antonio, TX; October 21-24, 2016.

11. Wollschlaeger BA, Montejano LB, Willson TM, Ronquest NA, Juneau PL, Nadipelli VR. Factors associated with buprenorphine medication-assisted treatment adherence in patients diagnosed with opioid use disorder. Proceedings of the 29th Annual US Psychiatric & Mental Health Congress. San Antonio, TX; October 21-24, 2016.
12. Tkacz J, Brady B, Nadipelli V, Volpicelli J, Ronquest N, Un H, Ruetsch C. Opioid use disorder population: who is at risk of medication assisted treatment non-adherence? Proceedings of the American Association for the Treatment of Opioid Dependence (AATOD) Conference. Baltimore, Maryland; October 29 to November 1, 2016.
13. Cranmer H, Ronquest NA, Barnes A-M, Nadipelli VR, Akehurst R. To what extent does the published economic analyses of treatments for opioid use disorder capture its chronic, relapsing nature and its impact on society? Proceedings of the Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress. Vienna, Austria; October 29 to November 2, 2016.
14. Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Health-related quality of life in opioid use disorder measured by utilities: a systemic literature review. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress. Vienna, Austria; October 29 to November 2, 2016.
15. Elroy PW, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Evaluating the effectiveness of treatments of opioid use disorder based on recovery outcomes: how to bridge the disconnect between clinical trial outcomes and recovery outcomes. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress. Vienna, Austria; October 29 to November 2, 2016.
16. Wollschlaeger BA, Ronquest NA, Montejano LB, Willson TM, Nadipelli VR. Narcotic Pain medication and other concomitant pain medication use before and after buprenorphine maintenance treatment initiation in patients with opioid dependence. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress. Vienna, Austria; October 29 to November 2, 2016.

Treatment of Schizophrenia

1. Laffont CM, Ivaturi V, Gobburu J, Gopalakrishnan M, Zhang W, Jones JP III, Twumasi-Ankrah P, Heidbreder C, Nasser AF. Exposure response analysis for a new once a month long acting risperidone for schizophrenia. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). San Diego, CA; March 8-12, 2016.
2. Konsoula Z, Heidbreder C, Twumasi-Ankrah P, Agarwal S, Jones JP III, Nasser AF. Association of genetic polymorphisms and response to RBP-7000 in patients with schizophrenia. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). San Diego, CA; March 8-12, 2016.